Faricimab appears comparable to ranibizumab through 52 weeks
- Posted on: Oct 13 2020
- Leave a response
This phase 2 trial assessed extended dosing of faricimab compared with monthly ranibizumab for neovascular AMD.
Source: AAO
Posted in: Uncategorized
